GlassScriptPhysician profile
Edmee Rodriguez
NPI 1346260544
$6,038.43
in general payments reported to CMS, 2019-2025
30 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $485 · 2021: $344 · 2022: $663 · 2023: $791 · 2024: $1,633 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.84 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,278.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $810.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $648.14 | 2019-2024 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $241.38 | 2024-2025 | Rexulti |
| Pfizer INC. | $237.17 | 2019-2024 | |
| Abbvie INC. | $217.35 | 2023-2024 | Vraylar |
| Inspire Medical Systems, INC. | $209.61 | 2023-2025 | Inspire |
| Allergan, INC. | $147.07 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $144.18 | 2024 | Ingrezza |
| Intuitive Surgical, INC. | $129.29 | 2024 | |
| Phathom Pharmaceuticals, INC. | $118.70 | 2025 | Voquezna |
| Dexcom, INC. | $99.86 | 2023 | Dexcom G7 Gss (161) |
| Amgen INC. | $99.51 | 2019-2024 | Prolia, Evenity |
| Abbott Laboratories | $87.35 | 2023 | Freestyle Libre 3 |
| Genzyme Corporation | $78.88 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.49 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $55.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $50.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $50.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.84 | 2019-2024 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $38.08 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $35.41 | 2025 | |
| Sanofi Pasteur INC. | $32.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.09 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $17.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.99 | 2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $12.51 | 2019 | |
| Amarin Pharma, INC. | $11.02 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmee Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.